Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | AOC2 | O75106 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750994 | 0.88 | RIPK1 (0.41) | RIPK1HDAC11CCR3MCHR1HTR2C | |
| SCHEMBL1750995 | 0.88 | RIPK1 (0.41) | RIPK1HDAC11CCR3MCHR1HTR2C | |
| SCHEMBL1750321 | 0.85 | PDE5A (0.47) | RIPK1HDAC11HCRTR1HCRTR2 | |
| SCHEMBL12529190 | 0.84 | HDAC11 (0.38) | RIPK1HDAC11HCRTR1HCRTR2 | |
| SCHEMBL20869242 | 0.81 | ALDH1A1 (0.54) | RIPK1ALDH1A1HDAC11CCR3HCRTR1 | |
| SCHEMBL1749984 | 0.80 | HDAC11 (0.42) | RIPK1HDAC11HCRTR1HCRTR2AOC2 | |
| SCHEMBL1749988 | 0.80 | HDAC11 (0.42) | RIPK1HDAC11HCRTR1HCRTR2AOC2 | |
| SCHEMBL20118241 | 0.79 | ALDH1A1 (0.56) | RIPK1ALDH1A1 | |
| SCHEMBL13299250 | 0.79 | PDE5A (0.43) | RIPK1HDAC11HCRTR1HCRTR2 | |
| SCHEMBL1750077 | 0.78 | PDE7B (0.45) | RIPK1ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | claimed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | claimed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| EP-2035379-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | RIPK1 2806/4885ALDH1A1 75/4885HDAC11 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.